Subscribe to our Email Alerts

ASX Announcements


 
Aug 27, 2024    H1 2024 financial results  
 
Aug 27, 2024    Half Yearly Report and Accounts  
 
Aug 19, 2024    Investor roadshow presentation, 19 August 2024  
 
Aug 16, 2024    Change of Director's Interest Notice - J Basile  
 
Aug 09, 2024    NNZ-2591 Angelman top-line results presentation  
 
Aug 09, 2024    Phase 2 trial shows significant improvements in Angelman  
 
Aug 07, 2024    Trading Halt  
 
Aug 07, 2024    Pause in Trading  
 
Aug 07, 2024    Q2 2024 update  
 
Jul 25, 2024    Neuren to participate in upcoming US investor conferences  
 
Jul 19, 2024    Ceasing to be a substantial holder  
 
Jul 19, 2024    Neuren receives Rare Pediatric Disease Designation from FDA  
 
Jul 02, 2024    Final Director's Interest Notice - T Scott  
 
Jun 17, 2024    Application for quotation of securities - NEU  
 
Jun 13, 2024    Change of Director's Interest Notice - J Basile  
 
May 29, 2024    Corporate Presentation, 29 May 2024  
 
May 28, 2024    Results of Meeting  
 
May 28, 2024    AGM Chair Address & CEO Presentation  
 
May 27, 2024    Pitt Hopkins syndrome Phase 2 trial results presentation  
 
May 27, 2024    Phase 2 trial shows significant improvements in Pitt Hopkins  
 
May 23, 2024    Trading Halt  
 
May 16, 2024    Neuren CEO to present at BIO & Jefferies conferences in US  
 
May 15, 2024    Investor presentation, 15 May 2024  
 
May 09, 2024    DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m  
 
May 07, 2024    Notification of cessation of securities - NEU  
 
Apr 26, 2024    Notification of cessation of securities - NEU  
 
Apr 26, 2024    Virtual AGM online guide  
 
Apr 26, 2024    Notice of Annual General Meeting/Proxy Form  
 
Apr 24, 2024    Q1 2024 quarterly activity and cash flow report  
 
Apr 23, 2024    Trofinetide accepted for Priority Review by Health Canada  
 
Apr 23, 2024    Appendix 4G  
 
Apr 23, 2024    2023 Annual Report to shareholders  
 
Apr 08, 2024    Application for quotation of securities - NEU  
 
Mar 12, 2024    Application for quotation of securities - NEU  
 
Feb 29, 2024    2023 Results webinar  
 
Feb 29, 2024    Neuren reports profit of $157 million for 2023  
 
Feb 29, 2024    Appendix 4E and 2023 full year accounts  
 
Feb 29, 2024    Neuren 2023 results investor webinar on 29 February 2024  
 
Feb 28, 2024    DAYBUE net sales US$87.1 million in Q4 2023  
 
Feb 16, 2024    Comment on research report  
 
Feb 16, 2024    Pause in Trading  
 
Feb 08, 2024    Notification regarding unquoted securities - NEU  
 
Feb 01, 2024    Application for quotation of securities - NEU  
 
Jan 31, 2024    Q4 2023 Appendix 4C Cash Flow Report  
 
Jan 31, 2024    Q4 2023 quarterly activity report  
 
Dec 20, 2023    Completion of enrolment in Neuren's Angelman P2 trial  
 
Dec 19, 2023    Application for quotation of securities - NEU  
 
Dec 18, 2023    Investor presentation, 18 December 2023  
 
Dec 18, 2023    P2 trial shows significant improvements in Phelan-McDermid  
 
Dec 14, 2023    Trading Halt  
 
Dec 05, 2023    Neuren completes enrolment in Pitt Hopkins Phase 2 trial  
 
Nov 20, 2023    Comment on media speculation  
 
Nov 13, 2023    Neuren completes Phelan-McDermid syndrome Phase 2 trial  
 
Nov 08, 2023    Investor presentation, 8 November 2023  
 
Nov 03, 2023    DAYBUE net sales US$66.9 million in Q3 2023  
 
Oct 20, 2023    Q3 2023 quarterly activity and cash flow report  
 
Sep 14, 2023    Change of Director's Interest Notice - J Basile  
 
Sep 01, 2023    S&P DJI Announces September 2023 Quarterly Rebalance  
 
Aug 28, 2023    Investor presentation, 28 August 2023  
 
Aug 28, 2023    Neuren reports 2023 half-year profit after tax of $48m  
 
Aug 28, 2023    Half Yearly Report and Accounts  
 
Aug 25, 2023    Notification of half-year results & investor web conference  
 
Jul 31, 2023    Q2 2023 quarterly activity and cash flow report  
 
Jul 27, 2023    Neuren receives US$100m for expanded DAYBUE agreement  
 
Jul 14, 2023    Investor web conference presentation, 14 July 2023  
 
Jul 14, 2023    Neuren and Acadia expand global partnership for trofinetide  
 
Jun 30, 2023    Neuren completes enrolment in Phelan-McDermid Phase 2 trial  
 
Jun 28, 2023    Neuren opens first site in US for Prader-Willi Phase 2 trial  
 
Jun 14, 2023    Change of Director's Interest Notice  
 
Jun 07, 2023    Neuren receives US$40m milestone payment  
 
Jun 05, 2023    Neuren presenting at Jefferies Global Healthcare Conference  
 
May 30, 2023    Results of Meeting  
 
May 30, 2023    AGM Chair Address & CEO Presentation  
 
Apr 28, 2023    Notice of Annual General Meeting/Proxy Form  
 
Apr 28, 2023    Virtual AGM online guide  
 
Apr 28, 2023    Q1 2023 quarterly activity and cash flow report  
 
Apr 27, 2023    Appendix 4G  
 
Apr 27, 2023    2022 Annual Report to shareholders  
 
Apr 18, 2023    DAYBUE (trofinetide) launched in US - Neuren earns US$40m  
 
Mar 27, 2023    Application for quotation of securities - NEU  
 
Mar 14, 2023    Investor Presentation, 14 March 2023  
 
Mar 13, 2023    Notification of investor webinar  
 
Mar 13, 2023    FDA approves Daybue - the first treatment for Rett syndrome  
 
Mar 02, 2023    Initial Director's Interest Notice  
 
Mar 02, 2023    Neuren appoints Joe Basile to board of directors  
 
Mar 01, 2023    Investor presentation, 1 March 2023  
 
Feb 24, 2023    Investor Presentation, 24 February 2023  
 
Feb 24, 2023    Neuren reports 2022 full-year results  
 
Feb 24, 2023    Appendix 4E and 2022 full year accounts  
 
Feb 21, 2023    Application for quotation of securities - NEU  
 
Jan 31, 2023    Q4 2022 quarterly activity and cash flow report  
 
Jan 23, 2023    Prader-Willi syndrome IND for NNZ-2591 approved by FDA  
 
Dec 23, 2022    Neuren submits IND & first patients complete Phase 2 trials  
 
Dec 07, 2022    Becoming a substantial holder  
 
Dec 02, 2022    Ceasing to be a substantial holder  
 
Nov 23, 2022    Change in substantial holding  
 
Oct 27, 2022    Q3 2022 quarterly activity and cash flow report  
 
Oct 20, 2022    Neuren receives US$10 million milestone payment  
 
Sep 14, 2022    Investor presentation, 14 September 2022  
 
Sep 13, 2022    Rett Syndrome NDA accepted for Priority Review by FDA  
 
Aug 24, 2022    Half-year shareholder update  
 
Aug 24, 2022    Half Yearly Report and Accounts  
 
Aug 08, 2022    Investor presentation, 8 August 2022  
 
Aug 08, 2022    Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS  
 
Jul 29, 2022    Quarterly Activities/Appendix 4C Cash Flow Report  
 
Jul 19, 2022    Acadia submits Rett Syndrome New Drug Application to the FDA  
 
Jul 12, 2022    Neuren commences Phase 2 trial of NNZ-2591 in Angelman  
 
Jul 08, 2022    Notification regarding unquoted securities - NEU  
 
Jul 08, 2022    Neuren appoints Chief Medical Officer in United States  
 
May 30, 2022    Results of Meeting  
 
May 30, 2022    AGM Chairman's Address & CEO Presentation  
 
Apr 29, 2022    Quarterly Activities/Appendix 4C Cash Flow Report  
 
Apr 28, 2022    Virtual AGM online guide  
 
Apr 28, 2022    Notice of Annual General Meeting/Proxy Form  
 
Apr 27, 2022    Change in substantial holding  
 
Apr 27, 2022    Appendix 4G  
 
Apr 27, 2022    Annual Report to shareholders  
 
Mar 25, 2022    FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial  
 
Mar 23, 2022    FDA approval for Phelan-McDermid IND and Phase 2 trial  
 
Mar 11, 2022    Ethics approval for Angelman Phase 2 trial in Australia  
 
Feb 25, 2022    Investor presentation 25 Feb 2022  
 
Feb 25, 2022    FDA approval for Angelman IND and Phase 2 trial  
 
Feb 24, 2022    2021 Results - a transformational year for Neuren  
 
Feb 24, 2022    Preliminary Final Report and 2021 Full Year Accounts  
 
Feb 03, 2022    Notification regarding unquoted securities - NEU  
 
Feb 01, 2022    Neuren appoints Vice President, Corporate Development  
 
Jan 31, 2022    Q4 2021 quarterly activity and cash flow report  
 
Dec 10, 2021    Becoming a substantial holder  
 
Dec 07, 2021    Positive topline results from Phase 3 trial in Rett syndrome  
 
Nov 10, 2021    Neuren presenting at Bell Potter Healthcare Conference  
 
Oct 28, 2021    Q3 2021 quarterly activity and cash flow report  
 
Oct 21, 2021    Neuren receives feedback on IND for Phelan-McDermid syndrome  
 
Oct 20, 2021    Change of Director's Interest Notice - D Angus  
 
Oct 11, 2021    US patent to 2034 granted for Neuren's NNZ-2591 in autism  
 
Oct 08, 2021    Change of Director's Interest Notice - J Harry  
 
Oct 08, 2021    Change of Director's Interest Notice - J Pilcher  
 
Oct 08, 2021    Change of Director's Interest Notice - P Davies  
 
Oct 08, 2021    Application for quotation of securities - NEU  
 
Oct 06, 2021    Update - Proposed issue of securities - NEU  
 
Oct 06, 2021    $3.3 million raised from oversubscribed SPP  
 
Oct 01, 2021    Feedback on Angelman IND and submission of Pitt Hopkins IND  
 
Sep 21, 2021    IND application submitted for NNZ-2591 in Phelan-McDermid  
 
Sep 17, 2021    Share Purchase Plan Offer Booklet  
 
Sep 16, 2021    Section 708A Notice  
 
Sep 16, 2021    New patent issued to 2032 for Neuren's trofinetide in Brazil  
 
Sep 16, 2021    Application for quotation of securities - NEU  
 
Sep 13, 2021    Investor Presentation, 13 September 2021  
 
Sep 13, 2021    Proposed issue of securities - NEU  
 
Sep 13, 2021    Placement to accelerate NNZ-2591 across 4 indications  
 
Sep 10, 2021    Notification of investor presentation, 9.00 AEST 13 Sept 21  
 
Sep 09, 2021    Trading Halt  
 
Sep 03, 2021    FDA grants Orphan Drug designation for Prader-Willi syndrome  
 
Sep 01, 2021    Angelman IND and Ethics applications submitted for NNZ-2591  
 
Sep 01, 2021    Trofinetide Rett syndrome clinical trial in girls aged 2-5  
 
Aug 30, 2021    R&D Tax Incentive Advance Overseas Finding Approval  
 
Aug 25, 2021    Half-year shareholder update  
 
Aug 25, 2021    Half Yearly Report and Accounts  
 
Aug 17, 2021    Notification of investor webinar  
 
Aug 05, 2021    Phase 3 enrolment successfully completed, results in Q4 2021  
 
Jul 30, 2021    Q2 2021 quarterly activity and cash flow report  
 
Jun 28, 2021    Change of Director's Interest Notice  
 
Jun 22, 2021    Results of Meeting  
 
Jun 22, 2021    AGM Chairman's Address and CEO Presentation  
 
Jun 16, 2021    Change of Director's Interest Notice  
 
Jun 15, 2021    Investor presentation, 15 June 2021  
 
Jun 15, 2021    Initial Director's Interest Notice  
 
Jun 15, 2021    Neuren CEO Jon Pilcher appointed to board of directors  
 
Jun 10, 2021    Neuren to present at MST Access investor conference  
 
Jun 10, 2021    Update - Annual General Meeting 2021  
 
Jun 01, 2021    Positive FDA meetings enable INDs for three Phase 2 trials  
 
May 21, 2021    Virtual AGM online guide  
 
May 21, 2021    Notice of Annual General Meeting/Proxy Form  
 
Apr 29, 2021    New patent issued to 2032 for Neuren's trofinetide in Canada  
 
Apr 27, 2021    Appendix 4G  
 
Apr 27, 2021    Annual Report to shareholders  
 
Apr 22, 2021    Quarterly report and cash flow statement for Q1 2021  
 
Mar 23, 2021    Investor presentation, 23 March 2021  
 
Mar 10, 2021    Neuren successfully completes manufacturing for Phase 2  
 
Feb 24, 2021    Neuren corporate presentation, 24 February 2021  
 
Feb 24, 2021    Neuren approaching transforming milestones in 2021  
 
Feb 24, 2021    Preliminary Final Report and 2020 full year accounts  
 
Feb 18, 2021    Change of Director's Interest Notice  
 
Feb 17, 2021    Notification of investor briefing webinar  
 
Feb 16, 2021    Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline  
 
Feb 15, 2021    Successful Phase 1 trial for Neuren's NNZ-2591  
 
Jan 29, 2021    Quarterly report and cash flow statement for Q4 2020  
 
Jan 11, 2021    European Commission grants 3 NNZ-2591 Orphan designations  
 
Dec 07, 2020    Notification of investor briefing webinar  
 
Dec 07, 2020    Positive opinion for all 3 Orphan applications in Europe  
 
Nov 19, 2020    Approval received for final stage of NNZ-2591 clinical trial  
 
Oct 29, 2020    Quarterly report and cash flow statement for Q3 2020  
 
Sep 29, 2020    Neuren requests Orphan designations for NNZ-2591 in Europe  
 
Sep 22, 2020    Neuren initiates manufacture of NNZ-2591 for Phase 2 trials  
 
Aug 26, 2020    Half-year Shareholder Update  
 
Aug 26, 2020    Half Yearly Report and Accounts  
 
Aug 18, 2020    Corporate presentation, 18 August 2020  
 
Aug 11, 2020    Change of Director's Interest Notice  
 
Aug 07, 2020    Appendix 2A  
 
Aug 07, 2020    Change of Director's Interest Notice  
 
Aug 05, 2020    Completion of Share Purchase Plan  
 
Jul 30, 2020    Appointment of CFO & Company Secretary  
 
Jul 27, 2020    Q2 2020 Activity Report and Cash Flow Report  
 
Jul 14, 2020    Final share buy-back notice - Appendix 3F  
 
Jul 14, 2020    Announcement of buy-back - Appendix 3C  
 
Jul 14, 2020    Publications and presentations for trofinetide and NNZ-2591  
 
Jul 13, 2020    Appendix 3G  
 
Jul 09, 2020    Share Purchase Plan Offer Booklet  
 
Jul 06, 2020    Section 708A notice  
 
Jul 06, 2020    Appendix 2A  
 
Jul 01, 2020    Electing to receive SPP documents by e-mail  
 
Jun 29, 2020    Results of Meeting  
 
Jun 29, 2020    AGM Chairman's Address and CEO Presentation  
 
Jun 29, 2020    Proposed issue of Securities - NEU  
 
Jun 29, 2020    Neuren successfully completes $20m capital raising  
 
Jun 25, 2020    Trading Halt  
 
Jun 16, 2020    Temporary enrolment pause ended in Phase 3 trial in the US  
 
Jun 02, 2020    Change of Director's Interest Notice  
 
Jun 01, 2020    Change of Director's Interest Notice  
 
May 29, 2020    Final Director's Interest Notice  
 
May 28, 2020    Virtual AGM online guide  
 
May 28, 2020    Notice of Annual General Meeting/Proxy Form  
 
May 27, 2020    Neuren announces changes to leadership team  
 
May 07, 2020    Neuren commences first clinical trial for NNZ-2591  
 
Apr 29, 2020    Appendix 4G  
 
Apr 29, 2020    Annual Report 2019  
 
Apr 17, 2020    Appendix 4C - quarterly  
 
Apr 17, 2020    Q1 2020 Activity Report  
 
Apr 06, 2020    Corporate presentation, 6 April 2020  
 
Apr 02, 2020    First patent in Israel granted for trofinetide  
 
Mar 26, 2020    Change of Director's Interest Notice  
 
Mar 26, 2020    International institution acquires 14% of Neuren  
 
Mar 24, 2020    Change of Director's Interest Notice  
 
Mar 24, 2020    Temporary pause in new enrolments for LAVENDER trial in US  
 
Mar 20, 2020    Trading Halt  
 
Mar 17, 2020    Neuren to capture substantially greater value after Phase 3  
 
Mar 10, 2020    Additional information  
 
Mar 06, 2020    Compelling results for 2591 dose ranging study in PMS model  
 
Mar 04, 2020    Commentary on potential benefit to Neuren of RPD designation  
 
Mar 04, 2020    Rare Pediatric Disease designation received from FDA  
 
Feb 26, 2020    5 Orphan Drug programs and Rett in Phase 3 funded by partner  
 
Feb 26, 2020    Appendix 4E and 2019 full year accounts  
 
Feb 19, 2020    Update on trofinetide Phase 3 trial in Rett syndrome  
 
Jan 28, 2020    Appendix 4C - quarterly  
 
Dec 12, 2019    2019 year-end update and 2020 outlook  
 
Dec 03, 2019    Patent to 2034 granted in Europe for Neuren's NNZ-2591  
 
Oct 31, 2019    Phase 3 trial of trofinetide in Rett syndrome commences  
 
Oct 18, 2019    Neuren Corporate Presentation, October 2019  
 
Oct 17, 2019    Appendix 4C - quarterly  
 
Oct 16, 2019    FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins  
 
Oct 16, 2019    Pause in Trading  
 
Oct 11, 2019    FDA grants Orphan Drug Designation for NNZ-2591 in Angelman  
 
Sep 20, 2019    Neuren approaching key milestones in Q4 2019  
 
Aug 28, 2019    Neuren advances pipeline for neurodevelopmental disorders  
 
Aug 28, 2019    Half Yearly Report and Accounts  
 
Aug 16, 2019    New patent granted for Neuren's NNZ-2591 in Japan  
 
Jul 31, 2019    Appendix 4C - quarterly  
 
Jul 29, 2019    Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA  
 
Jul 16, 2019    Neuren receives final payment from Lanstead Capital  
 
May 28, 2019    Results of Meeting  
 
May 28, 2019    Chairman's Address at 2019 Annual Meeting of Shareholders  
 
May 17, 2019    Validation for NNZ-2591 neurodevelopmental disorder pipeline  
 
May 17, 2019    NNZ-2591 positive effects in Pitt Hopkins syndrome model  
 
May 17, 2019    NNZ-2591 positive effects in Angelman syndrome model  
 
Apr 30, 2019    Appendix 4C - quarterly  
 
Apr 29, 2019    Notice of Annual General Meeting/Proxy Form  
 
Apr 26, 2019    Appendix 4G  
 
Apr 26, 2019    Annual Report to shareholders  
 
Apr 26, 2019    Update on development plan for NNZ-2591  
 
Mar 28, 2019    Neuren's Rett syndrome Phase 2 trial published in Neurology  
 
Feb 27, 2019    Fundamentals strong as Neuren advances neuroscience pipeline  
 
Feb 27, 2019    Preliminary Final Report and statutory accounts  
 
Feb 18, 2019    NNZ-2591 positive effects in Phelan-McDermid syndrome model  
 
Feb 04, 2019    Plans for Phase 3 trial in Rett syndrome  
 
Feb 01, 2019    Neuren retains ex-North America, appoints investment bank  
 
Jan 31, 2019    Appendix 4C - quarterly  
 
Jan 03, 2019    Final Director's Interest Notice  
 
Dec 31, 2018    Ceasing to be a substantial holder  
 
Dec 18, 2018    2018 Year-end Business Update  
 
Dec 17, 2018    Larry Glass to retire as a director and continue as CSO  
 
Nov 02, 2018    Presentation at AusBiotech Invest and Partnering 2018  
 
Oct 31, 2018    Appendix 4C - quarterly  
 
Oct 26, 2018    Trofinetide ex-North America exclusive negotiation period  
 
Oct 17, 2018    Neuren and ACADIA hold Rett syndrome SAB meeting  
 
Oct 01, 2018    Change of Director's Interest Notice  
 
Sep 21, 2018    FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID  
 
Sep 06, 2018    Investor presentation, 6 September 2018  
 
Aug 31, 2018    Half Yearly Report and Accounts  
 
Aug 29, 2018    Neuren and Lanstead agree to pause settlements for 120 days  
 
Aug 22, 2018    Appointment of auditor  
 
Aug 22, 2018    Neuren receives initial payment of US$10 million from ACADIA  
 
Aug 16, 2018    Change of Director's Interest Notice  
 
Aug 15, 2018    Change of Director's Interest Notice  
 
Aug 07, 2018    Investor update  
 
Aug 07, 2018    Neuren and ACADIA announce agreement for North America  
 
Jul 31, 2018    Appendix 4C - quarterly  
 
Jul 09, 2018    Initial Director's Interest Notice  
 
Jul 05, 2018    Initial Director's Interest Notice  
 
Jul 05, 2018    Initial Director's Interest Notice  
 
Jul 04, 2018    Neuren announces new appointments to the board of directors  
 
Jun 18, 2018    Results of Meeting  
 
Jun 18, 2018    Chairman's Address at 2018 Annual Shareholders' Meeting  
 
May 30, 2018    Change of Director's Interest Notice  
 
May 30, 2018    Final share buy-back notice - Appendix 3F  
 
May 30, 2018    Announcement of buy-back - Appendix 3C  
 
May 23, 2018    Notice under section 708A(5)(e) of the Corporations Act  
 
May 23, 2018    Appendix 3B  
 
May 21, 2018    Neuren announces investment and exclusive negotiation period  
 
May 14, 2018    Notice of Annual General Meeting/Proxy Form  
 
May 08, 2018    Appendix 4G  
 
May 08, 2018    Annual Report to shareholders  
 
Apr 30, 2018    Appendix 4C - quarterly  
 
Apr 30, 2018    First patent in Japan granted for Neuren's trofinetide  
 
Mar 29, 2018    Full Year Statutory Accounts  
 
Mar 29, 2018    Disclosure under Listing Rule 4.3D  
 
Feb 28, 2018    Preliminary Final Report  
 
Jan 30, 2018    Appendix 4C - quarterly  
 
Dec 29, 2017    Final Director's Interest Notice  
 
Dec 29, 2017    Non-executive director retirement  
 
Dec 27, 2017    Change in substantial holding  
 
Dec 05, 2017    Neuren announces new US patent to be granted for NNZ-2591  
 
Nov 16, 2017    Consolidation/Split - NEU  
 
Nov 16, 2017    Notification under Listing Rule 7.20 of share reorganisation  
 
Oct 26, 2017    Appendix 4C - quarterly  
 
Oct 13, 2017    Neuren FDA meeting confirms Phase 3 plan for Rett syndrome  
 
Oct 06, 2017    Investor presentation, 6 October 2017  
 
Oct 05, 2017    Presentations and publication for Rett syndrome trials  
 
Aug 30, 2017    Change of Director's Interest Notice  
 
Aug 30, 2017    Change of Director's Interest Notice  
 
Aug 30, 2017    Change of Director's Interest Notice  
 
Aug 29, 2017    Notice under section 708A(5)(e) of the Corporations Act  
 
Aug 29, 2017    Appendix 3B  
 
Aug 29, 2017    Results of Meeting  
 
Aug 24, 2017    Neuren reports 2017 half-year results  
 
Aug 24, 2017    Half Yearly Report and Accounts  
 
Aug 14, 2017    Notice of special meeting of shareholders  
 
Jul 27, 2017    Appendix 4C - quarterly  
 
Jul 21, 2017    Becoming a substantial holder  
 
Jul 20, 2017    Neuren granted Type B Meeting with FDA for Rett syndrome  
 
Jul 19, 2017    Notice under section 708A(5)(e) of the Corporations Act  
 
Jul 19, 2017    Appendix 3B  
 
Jul 13, 2017    Notice under section 708A(5)(e) of the Corporations Act  
 
Jul 13, 2017    Appendix 3B  
 
Jun 29, 2017    Results of Meeting  
 
Jun 29, 2017    2017 AGM Chairman's Address  
 
Jun 29, 2017    Neuren secures funding for key activities for Rett syndrome  
 
Jun 28, 2017    Response to ASX Price Query  
 
Jun 27, 2017    Trading Halt  
 
Jun 02, 2017    Investor presentation, 2 June 2017  
 
May 31, 2017    Neuren announces grant of two new patents to 2032  
 
May 29, 2017    Notice of Annual General Meeting/Proxy Form  
 
May 08, 2017    Response to Appendix 4C Query  
 
Apr 28, 2017    Appendix 4C - quarterly  
 
Apr 28, 2017    Appendix 4G  
 
Apr 28, 2017    Annual Report to shareholders  
 
Apr 04, 2017    Neuren receives $1 million R&D Tax Incentive  
 
Apr 03, 2017    Investor presentation, 3 April 2017  
 
Mar 30, 2017    Full Year Statutory Accounts  
 
Mar 22, 2017    Trofinetide significant clinical benefit in Rett syndrome  
 
Mar 17, 2017    Trading Halt  
 
Feb 23, 2017    Preliminary Final Report  
 
Feb 02, 2017    Investor presentation, 2 February 2017  
 
Jan 31, 2017    Appendix 4C - quarterly  
 
Jan 30, 2017    Neuren completes Phase 2 trial in pediatric Rett syndrome  
 
Dec 06, 2016    Results of Meeting  
 
Nov 25, 2016    Investor presentation, 25 November 2016  
 
Nov 14, 2016    Notice of special meeting of shareholders  
 
Nov 14, 2016    Neuren completes enrolment in Rett syndrome Phase 2 trial  
 
Oct 31, 2016    Appendix 4C - quarterly  
 
Oct 28, 2016    Neuren receives $0.9m from exercise of last expiring options  
 
Oct 28, 2016    Appendix 3B  
 
Aug 31, 2016    Change of Director's Interest Notice  
 
Aug 31, 2016    Appendix 3B  
 
Aug 30, 2016    Half Yearly Report and Accounts  
 
Aug 25, 2016    Neuren expands Phase 2 Rett syndrome pediatric trial  
 
Jul 26, 2016    Appendix 4C - quarterly  
 
Jun 24, 2016    Neuren presents at Rettsyndrome.org 2016 Research Symposium  
 
Jun 22, 2016    Grant of new patent for Autism Spectrum Disorders  
 
May 31, 2016    Results of Meeting  
 
May 31, 2016    Chairman's Address to Shareholders  
 
May 16, 2016    Change of Director's Interest Notice  
 
May 13, 2016    Presentation at 6th Annual TBI Conference, Washington DC  
 
May 02, 2016    Notice of Annual General Meeting/Proxy Form  
 
Apr 29, 2016    Appendix 4C - quarterly  
 
Apr 26, 2016    Neuren Shareholder Update  
 
Apr 26, 2016    Results of Phase 2 trial in moderate to severe TBI  
 
Apr 22, 2016    Trading Halt  
 
Apr 18, 2016    Appendix 4G  
 
Apr 18, 2016    Annual Report to shareholders  
 
Apr 07, 2016    First subject commences Neuren's Rett syndrome Phase 2 trial  
 
Feb 25, 2016    Neuren reports 2015 full-year financial results  
 
Feb 25, 2016    Appendix 4E and Financial Report 31 December 2015  
 
Jan 29, 2016    Appendix 4C - quarterly  
 
Jan 11, 2016    Neuren Investor Presentation, 11 January 2016  
 
Jan 04, 2016    Neuren Shareholder Update, January 2016  
 
Dec 30, 2015    Appendix 3B  
 
Dec 07, 2015    Trofinetide successful in Phase 2 trial in Fragile X  
 
Dec 03, 2015    Trading Halt  
 
Nov 30, 2015    Grant of composition patent in Europe for Neuren's NNZ-2591  
 
Nov 17, 2015    Corporations Act Notice  
 
Nov 17, 2015    Appendix 3B  
 
Nov 09, 2015    Shareholders provide further support for Rett syndrome  
 
Oct 29, 2015    Neuren completes enrolment in INTREPID clinical trial  
 
Oct 21, 2015    Appendix 4C - quarterly  
 
Oct 13, 2015    IRSF confirms financial support for Neuren's clinical trials  
 
Oct 12, 2015    New US patent covering use of trofinetide for Rett syndrome  
 
Sep 29, 2015    Neuren provides update on Fragile X and INTREPID trials  
 
Aug 25, 2015    Half Yearly Report and Accounts 30 June 2015  
 
Aug 14, 2015    trofinetide confirmed as INN for Neuren's NNZ-2566  
 
Aug 13, 2015    Neuren confirms orphan drug designations in Europe  
 
Jul 31, 2015    Investor presentation, 31 July 2015  
 
Jul 30, 2015    Appendix 4C - quarterly  
 
Jul 29, 2015    Neuren reports progress in orphan drug programs  
 
Jun 01, 2015    Appendix 3B  
 
May 07, 2015    Appendix 3B  
 
Apr 28, 2015    Results of Meeting  
 
Apr 28, 2015    Chairman's Address to Shareholders  
 
Apr 22, 2015    Appendix 3B  
 
Apr 21, 2015    Appendix 4C - quarterly  
 
Mar 26, 2015    Appendix 3B  
 
Mar 25, 2015    Notice of Annual General Meeting/Proxy Form  
 
Mar 25, 2015    Annual Report to shareholders  
 
Mar 02, 2015    Neuren receives response to request for Breakthrough Therapy  
 
Feb 25, 2015    Neuren reports 2014 full-year financial results  
 
Feb 25, 2015    Preliminary Final Report and 2014 full year accounts  
 
Feb 16, 2015    FDA grants Neuren Orphan Drug designation for Rett syndrome  
 
Feb 06, 2015    Appendix 3B  
 
Feb 05, 2015    Change of Director's Interest Notice  
 
Jan 29, 2015    Updated Share Trading Policy  
 
Jan 28, 2015    Neuren announces trofinetide as proposed INN for NNZ-2566  
 
Jan 27, 2015    Appendix 3B  
 
Jan 22, 2015    Appendix 4C - quarterly  
 
Jan 08, 2015    Investor Presentation, 8 January 2015  
 
Jan 05, 2015    Response to ASX Price Query  
 
Dec 30, 2014    Neuren submits Orphan Drug/Breakthrough Therapy applications  
 
Dec 23, 2014    Appendix 3B  
 
Dec 03, 2014    Appendix 3B  
 
Nov 27, 2014    Investor presentation, 27 November 2014  
 
Nov 20, 2014    Appendix 3B  
 
Nov 12, 2014    Neuren successful in Rett syndrome Phase 2 trial  
 
Nov 10, 2014    Trading Halt  
 
Oct 28, 2014    Appendix 3B  
 
Oct 17, 2014    Appendix 4C - quarterly  
 
Oct 09, 2014    Change of Director's Interest Notice  
 
Oct 09, 2014    Appendix 3B  
 
Sep 24, 2014    Appendix 3B  
 
Sep 24, 2014    Issue of long term incentives  
 
Sep 24, 2014    Neuren to release Rett Syndrome trial results in November  
 
Sep 08, 2014    Enrolment commences in Neuren's Concussion Phase 2 trial  
 
Sep 04, 2014    Investor presentation, 4 September 2014  
 
Aug 29, 2014    Appendix 3B  
 
Aug 28, 2014    Neuren reports 2014 half-year financial results  
 
Aug 28, 2014    Half Yearly Report and Accounts  
 
Aug 15, 2014    Appendix 3B  
 
Aug 12, 2014    Neuren advances NNZ-2591 towards IND application  
 
Jul 22, 2014    Appendix 3B  
 
Jul 18, 2014    Appendix 4C - quarterly  
 
Jul 17, 2014    US$3m increase to US Army grant and INTREPID outlook update  
 
Jul 10, 2014    Neuren receives ethics approval to start Concussion trial  
 
Jun 26, 2014    Neuren completes enrolment in Phase 2 trial in Rett Syndrome  
 
Jun 25, 2014    Appendix 3B  
 
Jun 23, 2014    Neuren appoints CMC expert to leadership team  
 
Jun 04, 2014    Neuren receives new US patent for NNZ-2591  
 
Jun 03, 2014    Appendix 3B  
 
Jun 03, 2014    Appendix 3B  
 
May 30, 2014    Appendix 3B  
 
May 21, 2014    Neuren presents at International Meeting for Autism Research  
 
May 14, 2014    Appendix 3B  
 
Apr 30, 2014    Appendix 4C - quarterly  
 
Apr 30, 2014    Appendix 3B  
 
Apr 30, 2014    AGM Results of Meeting  
 
Apr 30, 2014    Chairman's AGM Address to Shareholders  
 
Apr 02, 2014    Presentation at Morgans Emerging Companies Conference  
 
Mar 27, 2014    Appendix 3B  
 
Mar 27, 2014    Notice of Annual General Meeting/Proxy Form  
 
Mar 27, 2014    Annual Report to shareholders  
 
Feb 27, 2014    Neuren reports financial results for 2013  
 
Feb 27, 2014    Preliminary Final Report and audited Financial Statements  
 
Feb 21, 2014    Appendix 3B  
 
Feb 14, 2014    Appendix 3B  
 
Jan 31, 2014    Appendix 4C - quarterly  
 
Jan 28, 2014    Neuren reports progress in NNZ-2566 clinical trial programs  
 
Jan 15, 2014    Appendix 3B  
 
Jan 02, 2014    Appendix 3B  
 
Nov 29, 2013    Appendix 3B  
 
Nov 27, 2013    Appendix 3B  
 
Nov 27, 2013    Neuren Share Purchase Plan raises $2 million  
 
Nov 20, 2013    Ceasing to be a substantial holder  
 
Nov 19, 2013    Investor presentation, 19 November 2013  
 
Nov 15, 2013    Appendix 3B  
 
Nov 14, 2013    Change in substantial holding  
 
Nov 12, 2013    Appendix 3B  
 
Nov 06, 2013    Change of Director's Interest Notice  
 
Nov 04, 2013    Share Purchase Plan record date  
 
Nov 04, 2013    SPP Certification  
 
Nov 04, 2013    Appendix 3B  
 
Oct 31, 2013    Becoming a substantial holder  
 
Oct 30, 2013    Share Purchase Plan offer documents  
 
Oct 30, 2013    Appendix 4C - quarterly  
 
Oct 30, 2013    Orphan drug designation from FDA for NNZ-2566 in Fragile X  
 
Oct 28, 2013    Section 708A(5)e Notice  
 
Oct 28, 2013    Appendix 3B  
 
Oct 22, 2013    Placement of $21.5m to accelerate execution of strategy  
 
Oct 18, 2013    Neuren receives Fast Track designation for Fragile X  
 
Oct 18, 2013    Trading Halt  
 
Oct 10, 2013    Appendix 3B  
 
Oct 09, 2013    Response to ASX Price Query  
 
Oct 09, 2013    Investor presentation  
 
Oct 01, 2013    Neuren data presented at Fragile X Foundation meeting  
 
Sep 26, 2013    Appendix 3B  
 
Sep 19, 2013    Change of Director's Interest Notice  
 
Sep 11, 2013    Appendix 3B  
 
Sep 09, 2013    Neuren opens new IND for NNZ-2566 in Fragile X Syndrome  
 
Sep 04, 2013    Final Director's Interest Notice  
 
Sep 02, 2013    Neuren announces changes to its leadership team  
 
Aug 29, 2013    Half Yearly Report and Accounts  
 
Aug 05, 2013    Notice under section 708A(5)(e) of the Corporations Act  
 
Aug 05, 2013    Response to social media commentary re Rett trial  
 
Aug 05, 2013    Trading Halt Request  
 
Aug 05, 2013    Trading Halt  
 
Jul 31, 2013    Appendix 4C - quarterly  
 
Jul 30, 2013    Investor presentation July 2013  
 
Jul 30, 2013    Appendix 3B Option Exercise  
 
Jul 29, 2013    Results in Fragile X Model with NNZ 2591  
 
Jul 26, 2013    Response to ASX Price Query  
 
Jul 12, 2013    Neuren receives two new patents  
 
Jul 11, 2013    Notice under section 708A(5)(e) of the Corporations Act  
 
Jul 11, 2013    Appendix 3B Option Exercise amended  
 
Jul 11, 2013    Appendix 3B Option Exercise  
 
Jun 26, 2013    Notice under section 708A(5)(e) of the Corporations Act  
 
Jun 26, 2013    Appendix 3B Option Exercise  
 
Jun 25, 2013    Response to ASX Price Query Letter  
 
Jun 18, 2013    Notice under section 708A(5)(e) of the Corporations Act  
 
Jun 12, 2013    Appendix 3B Option Exercise  
 
Jun 05, 2013    FDA Fast Track granted for NNZ2566 Rett program  
 
May 29, 2013    Change of Director's Interest Notice  
 
May 29, 2013    Appendix 3B Equity Performance Rights  
 
May 29, 2013    Appendix 3B Loan Funded Shares  
 
May 29, 2013    Notice under section 708A(5)(e) of the Corporations Act  
 
May 24, 2013    CFO appointment  
 
May 22, 2013    Final Director's Interest Notice  
 
May 22, 2013    Final Director's Interest Notice  
 
May 22, 2013    Appendix 3B Exercise of Options  
 
May 22, 2013    Lapse of Unlisted Options  
 
May 22, 2013    Change of Director's Interest Notice  
 
May 22, 2013    Change of Director's Interest Notice  
 
May 21, 2013    Investor Presentation May 2013  
 
May 20, 2013    Results of Meeting  
 
May 20, 2013    CEO Presentation to AGM  
 
May 20, 2013    Chairman's Address to AGM  
 
May 15, 2013    Response to ASX Price Query Letter  
 
Apr 30, 2013    Appendix 4C - quarterly  
 
Apr 19, 2013    Notice of Annual General Meeting/Proxy Form  
 
Apr 15, 2013    Shareholder Update  
 
Apr 04, 2013    Ceasing to be a substantial holder  
 
Mar 28, 2013    Annual Report to shareholders  
 
Feb 28, 2013    Preliminary Final Report  
 
Feb 01, 2013    Initial Director's Interest Notice  
 
Jan 31, 2013    Dr Richard Treagus joins Neuren Board  
 
Jan 31, 2013    Appendix 4C - quarterly  
 
Jan 09, 2013    Neuren appoints Nancy Jones SD Clinical & Medical Affairs  
 
Dec 24, 2012    Neuren IND open for Rett Phase II trial  
 
Dec 20, 2012    Appendix 3B  
 
Nov 30, 2012    Neuren TAP Conference presentation and Fragile X results  
 
Nov 22, 2012    Neuren completes Phase I NNZ2566 study/files Phase II IND  
 
Nov 09, 2012    Amended 2 - Change in substantial holding  
 
Nov 09, 2012    Amended Change in substantial holding  
 
Nov 09, 2012    Change in substantial holding  
 
Oct 31, 2012    Appendix 4C - quarterly  
 
Oct 25, 2012    Response to ASX Price Query  
 
Oct 19, 2012    NNZ2566 selected as Windhover Top 10 Neuroscience Project  
 
Aug 30, 2012    Half Yearly Report and Accounts  
 
Aug 09, 2012    Neuren appoints Joe Horrigan VP Clinical and Medical Affairs  
 
Aug 07, 2012    NNZ2566 Rationale in ASDs  
 
Jul 31, 2012    Appendix 4C - quarterly  
 
Jul 06, 2012    Neuren awarded Rett Syndrome trial grant  
 
Jun 08, 2012    Final Director's Interest Notice  
 
Jun 08, 2012    Initial Director's Interest Notice  
 
May 31, 2012    Results of Meeting  
 
May 31, 2012    CEO's address to AGM  
 
May 29, 2012    Neuren announces cancer xenograft testing results  
 
May 25, 2012    Change in substantial holding  
 
May 16, 2012    Rett Syndrome pre-IND meeting held with FDA  
 
May 02, 2012    Notice under section 708A(5)(e) of the Corporations Act  
 
Apr 30, 2012    Appendix 4C - quarterly  
 
Apr 27, 2012    Appendix 3B (exercise of options)  
 
Apr 27, 2012    Notice of Annual General Meeting/Proxy Form  
 
Apr 19, 2012    Response to ASX Price Query  
 
Mar 30, 2012    Neuren 2011 Annual Report  
 
Mar 08, 2012    Initial Director's Interest Notice  
 
Mar 08, 2012    Neuren appoints Bruce Hancox to board of directors  
 
Mar 08, 2012    Neuren presentation to Arrowhead TBI Conference  
 
Feb 29, 2012    Neuren 2011 Preliminary Final Report  
 
Jan 31, 2012    Appendix 4C - quarterly  
 
Dec 22, 2011    Neuren to proceed with oral NNZ2566 trial  
 
Dec 12, 2011    Change in substantial holding  
 
Dec 09, 2011    Response to ASX Price Query  
 
Nov 21, 2011    Neuren Completes Phase II trial Cohort 2  
 
Nov 07, 2011    Appendix 3B (exercise of options)  
 
Nov 03, 2011    Change in substantial holding  
 
Nov 03, 2011    Change in substantial holding  
 
Oct 28, 2011    Appendix 4C - quarterly  
 
Oct 26, 2011    Appendix 3B (amendment)  
 
Oct 26, 2011    Change of Director's Interest Notice  
 
Oct 26, 2011    Change of Director's Interest Notice  
 
Oct 26, 2011    Change of Director's Interest Notice  
 
Oct 26, 2011    Change of Director's Interest Notice  
 
Oct 26, 2011    Change of Director's Interest Notice  
 
Oct 26, 2011    Appendix 3B  
 
Oct 20, 2011    Response to ASX Price Query  
 
Aug 30, 2011    Half Yearly Report and Accounts  
 
Aug 17, 2011    Becoming a substantial holder  
 
Aug 16, 2011    Becoming a substantial holder  
 
Aug 16, 2011    Notice under section 708A(5)(e) of the Corporations Act  
 
Aug 16, 2011    Appendix 3B  
 
Aug 16, 2011    Neuren places $3m of rights issue shortfall  
 
Jul 29, 2011    Appendix 4C - quarterly  
 
Jul 27, 2011    NEU Broker Presentation July 2011  
 
Jul 22, 2011    Neuren CEO presentation to Bioshares Biotech Summit  
 
Jul 21, 2011    Change of Director's Interest Notice  
 
Jul 21, 2011    Change of Director's Interest Notice  
 
Jul 19, 2011    Appendix 3B  
 
Jul 19, 2011    Results of Neuren Rights Issue  
 
Jun 29, 2011    Neuren Confirms Despatch of Rights Issue Offer Documents  
 
Jun 28, 2011    Appendix 3B  
 
Jun 24, 2011    CEO presentation to AusBiotech New York  
 
Jun 20, 2011    Rights Issue Eligible Shareholder Notice  
 
Jun 20, 2011    Change in substantial holding  
 
Jun 15, 2011    Rights Issue Notice to Foreign Shareholders  
 
Jun 15, 2011    Rights Issue Notice to Optionholders  
 
Jun 15, 2011    Rights Issue Notice under Section 708AA  
 
Jun 15, 2011    Appendix 3B (renounceable rights issue)  
 
Jun 15, 2011    Neuren Rights Issue Letter of Offer (Australian residents)  
 
Jun 15, 2011    Neuren Rights Issue Offer Document (NZ residents)  
 
Jun 15, 2011    Neuren announces Renounceable Rights Issue  
 
Jun 06, 2011    Notice under section 708A(5)(e) of the Corporations Act  
 
Jun 06, 2011    Neuren completes placement and converts remaining note  
 
Jun 06, 2011    Appendix 3B (options)  
 
Jun 06, 2011    Appendix 3B (shares)  
 
Jun 03, 2011    Notice under section 708A(5)(e) of the Corporations Act  
 
Jun 03, 2011    Appendix 3B  
 
Jun 02, 2011    Notice under section 708A(5)(e) of the Corporations Act  
 
Jun 02, 2011    Appendix 3B  
 
May 31, 2011    Results of Annual Meeting  
 
May 31, 2011    Results of Special Meeting  
 
May 31, 2011    Neuren CEO Presentation to AGM  
 
May 20, 2011    Neuren reduces outstanding convertible note principal  
 
May 19, 2011    Neuren's Perseis selects lead antibodies  
 
May 13, 2011    Notice of Special Shareholders Meeting/Proxy Form  
 
May 11, 2011    Neuren Completes Phase II trial Cohort 1  
 
May 06, 2011    Notice under section 708A(5)(e) of the Corporations Act  
 
May 06, 2011    Appendix 3B  
 
May 05, 2011    Becoming a substantial holder  
 
May 04, 2011    Neuren Announces Private Placement and Rights Issue  
 
May 02, 2011    Trading Halt  
 
Apr 29, 2011    Notice of Annual General Meeting/Proxy Form  
 
Apr 29, 2011    Appendix 4C - quarterly  
 
Apr 27, 2011    Appendix 3B  
 
Apr 20, 2011    Notice under section 708A(5)(e) of the Corporations Act  
 
Apr 20, 2011    Appendix 3B  
 
Apr 20, 2011    Appendix 3B  
 
Mar 31, 2011    Annual Report to shareholders  
 
Mar 23, 2011    Appendix 3B  
 
Mar 22, 2011    Notice under section 708A(5)(e) of the Corporations Act  
 
Mar 21, 2011    Appendix 3B  
 
Mar 21, 2011    Appendix 3B  
 
Mar 21, 2011    Appendix 3B  
 
Mar 21, 2011    Results of Meeting  
 
Mar 10, 2011    Response to ASX Price Query  
 
Mar 03, 2011    Notice of Special Shareholders Meeting  
 
Feb 28, 2011    Preliminary Final Report  
 
Feb 21, 2011    Appendix 3B  
 
Feb 18, 2011    Notice under section 708A(5)(e) of the Corporations Act  
 
Feb 18, 2011    Appendix 3B  
 
Feb 08, 2011    Lapse of unquoted options  
 
Jan 31, 2011    Appendix 4C - quarterly  
 
Jan 21, 2011    Appendix 3B  
 
Jan 21, 2011    Appendix 3B (amended)  
 
Jan 19, 2011    Notice under section 708A(5)(e) of the Corporations Act  
 
Jan 19, 2011    Appendix 3B  
 
Jan 19, 2011    Appendix 3B  
 
Dec 22, 2010    Appendix 3B  
 
Dec 20, 2010    Notice under section 708A(5)(e) of the Corporations Act  
 
Dec 20, 2010    Securities Trading Policy  
 
Dec 20, 2010    Appendix 3B  
 
Dec 20, 2010    Appendix 3B  
 
Nov 22, 2010    Appendix 3B  
 
Nov 19, 2010    Notice under section 708A(5)(e) of the Corporations Act  
 
Nov 19, 2010    Appendix 3B  
 
Nov 19, 2010    Appendix 3B